Starpharma Holdings Limited (SPL.AX)
AUD 0.1
(1.02%)
AUD 0.1
(1.02%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -15.15 Million AUD | 38.56% |
| 2023 | -24.67 Million AUD | -3.26% |
| 2022 | -23.89 Million AUD | 16.65% |
| 2021 | -28.66 Million AUD | -33.79% |
| 2020 | -21.42 Million AUD | -50.34% |
| 2019 | -14.25 Million AUD | -38.59% |
| 2018 | -10.28 Million AUD | 32.41% |
| 2017 | -15.21 Million AUD | 28.53% |
| 2016 | -21.29 Million AUD | -12.38% |
| 2015 | -18.94 Million AUD | -29.51% |
| 2014 | -14.62 Million AUD | -68.45% |
| 2013 | -8.68 Million AUD | 50.8% |
| 2012 | -17.65 Million AUD | -40.04% |
| 2011 | -12.6 Million AUD | -0.33% |
| 2010 | -12.56 Million AUD | 11.05% |
| 2009 | -14.12 Million AUD | 24.58% |
| 2008 | -18.72 Million AUD | -1.42% |
| 2007 | -18.46 Million AUD | -33.31% |
| 2006 | -13.85 Million AUD | -33.52% |
| 2005 | -10.37 Million AUD | -43.23% |
| 2004 | -7.24 Million AUD | 7.99% |
| 2003 | -7.87 Million AUD | 11.23% |
| 2002 | -8.86 Million AUD | -58.82% |
| 2001 | -5.58 Million AUD | -57.56% |
| 2000 | -3.54 Million AUD | -51.56% |
| 1999 | -2.33 Million AUD | 8.0% |
| 1998 | -2.54 Million AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -4.95 Million AUD | 0.0% |
| 2024 Q4 | -14.35 Million AUD | 0.0% |
| 2024 FY | -15.15 Million AUD | 38.56% |
| 2023 Q2 | -13.2 Million AUD | 0.0% |
| 2023 FY | -24.67 Million AUD | -3.26% |
| 2023 Q4 | -11.46 Million AUD | 0.0% |
| 2022 FY | -23.89 Million AUD | 16.65% |
| 2022 Q4 | -11.55 Million AUD | 0.0% |
| 2022 Q2 | -12.34 Million AUD | 0.0% |
| 2021 Q2 | -14.65 Million AUD | 0.0% |
| 2021 Q4 | -14.01 Million AUD | 0.0% |
| 2021 FY | -28.66 Million AUD | -33.79% |
| 2020 Q4 | -12.29 Million AUD | 0.0% |
| 2020 Q2 | -9.13 Million AUD | 0.0% |
| 2020 FY | -21.42 Million AUD | -50.34% |
| 2019 FY | -14.25 Million AUD | -38.59% |
| 2019 Q2 | -7.26 Million AUD | 0.0% |
| 2019 Q4 | -10.13 Million AUD | 0.0% |
| 2018 Q4 | -4.05 Million AUD | 0.0% |
| 2018 FY | -10.28 Million AUD | 32.41% |
| 2018 Q2 | -6.22 Million AUD | 0.0% |
| 2017 Q2 | -8.33 Million AUD | 0.0% |
| 2017 FY | -15.21 Million AUD | 28.53% |
| 2016 FY | -21.29 Million AUD | -12.38% |
| 2016 Q2 | -10.03 Million AUD | 0.0% |
| 2015 Q4 | -10.41 Million AUD | 0.0% |
| 2015 Q2 | -8.53 Million AUD | 0.0% |
| 2015 FY | -18.94 Million AUD | -29.51% |
| 2014 FY | -14.62 Million AUD | -68.45% |
| 2014 Q4 | -9.05 Million AUD | 0.0% |
| 2014 Q2 | -5.57 Million AUD | 0.0% |
| 2013 Q2 | -1.82 Million AUD | 55.74% |
| 2013 Q1 | -4.12 Million AUD | 0.0% |
| 2013 Q3 | -1.9 Million AUD | -4.46% |
| 2013 Q4 | -3.39 Million AUD | -77.78% |
| 2013 FY | -8.68 Million AUD | 50.8% |
| 2012 Q1 | -2.76 Million AUD | 0.0% |
| 2012 FY | -17.65 Million AUD | -40.04% |
| 2012 Q4 | -4.12 Million AUD | 0.0% |
| 2012 Q3 | -4.12 Million AUD | 0.0% |
| 2012 Q2 | -4.12 Million AUD | -49.1% |
| 2011 FY | -12.6 Million AUD | -0.33% |
| 2011 Q3 | -2.76 Million AUD | 0.0% |
| 2011 Q1 | -2.71 Million AUD | 0.0% |
| 2011 Q4 | -2.76 Million AUD | 0.0% |
| 2011 Q2 | -2.76 Million AUD | -1.9% |
| 2010 Q3 | -2.71 Million AUD | 0.0% |
| 2010 FY | -12.56 Million AUD | 11.05% |
| 2010 Q2 | -2.71 Million AUD | 10.17% |
| 2010 Q1 | -3.02 Million AUD | 0.0% |
| 2010 Q4 | -2.71 Million AUD | 0.0% |
| 2009 Q2 | -3.02 Million AUD | 27.25% |
| 2009 Q3 | -3.02 Million AUD | 0.0% |
| 2009 Q4 | -3.02 Million AUD | 0.0% |
| 2009 Q1 | -4.15 Million AUD | 0.0% |
| 2009 FY | -14.12 Million AUD | 24.58% |
| 2008 Q2 | -4.15 Million AUD | -1.11% |
| 2008 Q3 | -4.15 Million AUD | 0.0% |
| 2008 FY | -18.72 Million AUD | -1.42% |
| 2008 Q4 | -4.15 Million AUD | 0.0% |
| 2008 Q1 | -4.11 Million AUD | 0.0% |
| 2007 FY | -18.46 Million AUD | -33.31% |
| 2007 Q4 | -4.11 Million AUD | 0.0% |
| 2007 Q1 | -3.46 Million AUD | 0.0% |
| 2007 Q3 | -4.11 Million AUD | 0.0% |
| 2007 Q2 | -4.11 Million AUD | -18.73% |
| 2006 Q1 | -2.59 Million AUD | 0.0% |
| 2006 Q4 | -3.46 Million AUD | 0.0% |
| 2006 Q3 | -3.46 Million AUD | 0.0% |
| 2006 FY | -13.85 Million AUD | -33.52% |
| 2006 Q2 | -3.46 Million AUD | -33.52% |
| 2005 FY | -10.37 Million AUD | -43.23% |
| 2005 Q3 | -2.59 Million AUD | 0.0% |
| 2005 Q4 | -2.59 Million AUD | 0.0% |
| 2005 Q2 | -2.59 Million AUD | -43.23% |
| 2005 Q1 | -1.81 Million AUD | 0.0% |
| 2004 Q4 | -1.81 Million AUD | 0.0% |
| 2004 Q1 | -1.96 Million AUD | 0.0% |
| 2004 Q2 | -1.81 Million AUD | 7.99% |
| 2004 Q3 | -1.81 Million AUD | 0.0% |
| 2004 FY | -7.24 Million AUD | 7.99% |
| 2003 Q2 | -1.96 Million AUD | 9.46% |
| 2003 Q4 | -1.96 Million AUD | 0.0% |
| 2003 Q3 | -1.96 Million AUD | 0.0% |
| 2003 Q1 | -2.17 Million AUD | 0.0% |
| 2003 FY | -7.87 Million AUD | 11.23% |
| 2002 Q4 | -2.17 Million AUD | 0.0% |
| 2002 Q3 | -2.17 Million AUD | 0.0% |
| 2002 Q1 | -1.38 Million AUD | 0.0% |
| 2002 Q2 | -2.17 Million AUD | -57.48% |
| 2002 FY | -8.86 Million AUD | -58.82% |
| 2001 Q1 | -886 Thousand AUD | 0.0% |
| 2001 Q2 | -1.38 Million AUD | -55.79% |
| 2001 Q4 | -1.38 Million AUD | 0.0% |
| 2001 Q3 | -1.38 Million AUD | 0.0% |
| 2001 FY | -5.58 Million AUD | -57.56% |
| 2000 Q2 | -886 Thousand AUD | -51.56% |
| 2000 FY | -3.54 Million AUD | -51.56% |
| 2000 Q4 | -886 Thousand AUD | 0.0% |
| 2000 Q3 | -886 Thousand AUD | 0.0% |
| 2000 Q1 | -584.58 Thousand AUD | 0.0% |
| 1999 FY | -2.33 Million AUD | 8.0% |
| 1999 Q1 | -635.39 Thousand AUD | 0.0% |
| 1999 Q2 | -584.58 Thousand AUD | 8.0% |
| 1999 Q3 | -584.58 Thousand AUD | 0.0% |
| 1999 Q4 | -584.58 Thousand AUD | 0.0% |
| 1998 Q4 | -635.39 Thousand AUD | 0.0% |
| 1998 Q2 | -635.39 Thousand AUD | 0.0% |
| 1998 Q3 | -635.39 Thousand AUD | 0.0% |
| 1998 FY | -2.54 Million AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AdAlta Limited | -5.26 Million AUD | -188.107% |
| Acrux Limited | -9.83 Million AUD | -54.149% |
| Botanix Pharmaceuticals Limited | -14.69 Million AUD | -3.123% |
| BTC Health Limited | 1.05 Million AUD | 1536.481% |
| Chimeric Therapeutics Limited | -12.3 Million AUD | -23.147% |
| Clarity Pharmaceuticals Ltd | -44.8 Million AUD | 66.163% |
| Clinuvel Pharmaceuticals Limited | 49.14 Million AUD | 130.843% |
| Biome Australia Limited | -1.91 Million AUD | -692.321% |
| Hexima Limited | -1 Million AUD | -1402.751% |
| Immutep Limited | -44.93 Million AUD | 66.266% |
| Memphasys Limited | -2.7 Million AUD | -460.614% |
| Neuren Pharmaceuticals Limited | 225.96 Million AUD | 106.709% |
| Noxopharm Limited | -7.53 Million AUD | -101.181% |
| Prescient Therapeutics Limited | -7.18 Million AUD | -110.94% |
| Race Oncology Limited | -13.38 Million AUD | -13.291% |
| Radiopharm Theranostics Limited | -47.2 Million AUD | 67.89% |
| Tissue Repair Ltd | -4.87 Million AUD | -210.893% |
| Biotron Limited | -5.15 Million AUD | -194.283% |
| Alterity Therapeutics Limited | -19.6 Million AUD | 22.665% |
| CSL Limited | 5.64 Billion AUD | 100.268% |
| EZZ Life Science Holdings Limited | 9.71 Million AUD | 256.012% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -938.909% |
| Bio-Gene Technology Limited | -3.06 Million AUD | -394.994% |
| Zelira Therapeutics Limited | -5.93 Million AUD | -155.278% |
| Patrys Limited | -3.53 Million AUD | -328.323% |
| Orthocell Limited | -11.68 Million AUD | -29.774% |
| Imugene Limited | -140.93 Million AUD | 89.244% |
| PYC Therapeutics Limited | -38.85 Million AUD | 60.988% |
| Proteomics International Laboratories Limited | -7.23 Million AUD | -109.623% |
| Cynata Therapeutics Limited | -8.8 Million AUD | -72.106% |
| Arovella Therapeutics Limited | -7.19 Million AUD | -110.745% |
| Nanollose Limited | -1.24 Million AUD | -1112.89% |
| Invex Therapeutics Ltd | -2.13 Million AUD | -610.48% |
| NeuroScientific Biopharmaceuticals Limited | -2.05 Million AUD | -637.105% |
| Amplia Therapeutics Limited | -4.42 Million AUD | -242.578% |
| Island Pharmaceuticals Limited | -2.87 Million AUD | -427.493% |
| Nyrada Inc. | -4.56 Million AUD | -232.41% |
| Telix Pharmaceuticals Limited | - AUD | Infinity% |
| Dimerix Limited | -25.05 Million AUD | 39.509% |
| PharmAust Limited | -6.65 Million AUD | -127.659% |
| AnteoTech Limited | -11.72 Million AUD | -29.27% |
| Paradigm Biopharmaceuticals Limited | -65.11 Million AUD | 76.719% |
| Recce Pharmaceuticals Ltd | -22.05 Million AUD | 31.256% |
| Avecho Biotechnology Limited | -4.58 Million AUD | -230.32% |
| Actinogen Medical Limited | -12.83 Million AUD | -18.07% |
| Immuron Limited | -5.8 Million AUD | -161.312% |
| Argenica Therapeutics Limited | -5.67 Million AUD | -167.298% |